More might per molecule. Explore A strong foundation. We got our start as a research firm, cutting our teeth in the industry by discovering new molecules. Our break-through work became a building block for new medicines. Soon thereafter, we expanded our repertoire. The science of giving a damn. While we continue to research new molecules, our capabilities now also include the clinical and commercial development of our drugs. More significant, though, is our increased involvement in patient communities. Patients, more than anyone else, are experts in the hematological diseases we’ve dedicated our lives to curing. Caring deeply about them and understanding their experiences gets us closer to our common goal. Next on the to-do list. Today, we continue to enhance our capabilities focused on becoming a fully integrated, clinical-stage biopharmaceutical company based in Watertown, MA, which means in addition to conducting groundbreaking research, we’re the ones who turn those findings into treatments and products. It’s a challenge, but it’s a welcome one. We will not stop because our patients don’t have the same luxury. 300 North Beacon Street, Suite 501 Watertown, MA 02472 617.679.1970 twitter linkedin instagram facebook glassdoor Privacy Policy Terms of Use © 2021 ALL RIGHTS RESERVED

Pipeline Explore After years of work in medicinal chemistry, we’ve built our clinical development pipeline by selecting the most promising drug targets and chemical assets that align with our strategic focus on rare hematologic diseases and cancers. Our pipeline consists of six product candidates, two of which we have exclusively out-licensed for further clinical development. Leveraging our strong heritage of research and development, we’ve created a pipeline of small-molecule drug candidates that we believe have differentiated capabilities for addressing indications with high unmet medical need in hemoglobinopathies and targeted oncology. Program Indication Development Stage Commercial Rights Core Focus Pursuing Partnerships Out-Licensed Programs PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ETAVOPIVAT PKR ACTIVATOR Sickle Cell Disease FT-7051 CBP/P300 INHIBITOR Metastatic Castration-Resistant Prostate Cancer (mCRPC)AR RESISTANT OLUTASIDENIB IDH1M INHIBITOR Acute Myeloid Leukemia OLUTASIDENIB IDH1M INHIBITOR Glioma FT-8225 FASN INHIBITOR Non-Alcoholic Steatohepatitis (NASH) BI-1701963 KRAS Solid Tumors 300 North Beacon Street, Suite 501 Watertown, MA 02472 617.679.1970 twitter linkedin instagram facebook glassdoor Privacy Policy Terms of Use © 2021 ALL RIGHTS RESERVED